Alkem Labs Receives Income Tax Order; No Material Financial Impact Expected
Alkem Laboratories received an Income Tax order for AY 2023-24, disallowing part of an 80IE deduction and involving transfer pricing adjustments. A tax amount of ₹333.38 crore is disputed, but no payment is due to MAT credit utilization. The company expects no material financial impact and will appeal the order.
The company explicitly stated that there is no material impact on financial, operational, or other activities due to the order, as there is no expected cash outflow. They believe the dispute is not tenable and plan to appeal.
The company received an order from the Income Tax Department, which could be seen as negative. However, the company states there is no material financial impact and they have grounds for appeal, leading to a neutral sentiment.
Alkem Laboratories Limited has received an order from the Deputy Commissioner of Income Tax, Central Circle 8(1), Mumbai, under the Income-tax Act, 1961. The order, dated 13th April 2026, pertains to the assessment year 2023-24 and involves the disallowance of a part of the deduction claimed under Section 80IE, in addition to a transfer pricing adjustment.
The Income Tax Authority has disputed a tax amount of ₹333.38 Crores (Rupees Three hundred thirty-three crore and thirty-eight lakhs). However, the company has stated that no amount is payable due to the utilization of available MAT credit. The order was received by the company on 24th April 2026.
Alkem Laboratories Limited believes the dispute is not tenable and possesses adequate factual and legal grounds to support its position. The company intends to pursue an appeal against the said order under the applicable laws. Consequently, there is no material impact on the financial, operational, or other activities of the company as no cash outflow is expected.
What to do with a filing like this
Alkem Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under regulatory impact. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alkem Laboratories Limited. Read the original for the full detail.